Clinical trials: Pharynx Carcinoma
Nasopharyngeal Neoplasms, Stomatitis
Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma
This is a prospective, observational study to analyze the clinical and dosimetric factors about the radiation oral mucositis caused by radical chemo-radiotherapy for nasopharyngeal carcinoma patients and try to find the…
- Trial name
- NCT02945878
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, PET/MR
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03657017
- Testing
- PET/MR
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune…
- Trial name
- AK112 (NCT07565389)
- Testing
- Ivonescimab 20 mg/kg
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- National University Hospital, Singapore
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal…
- Conditions
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma
- Trial name
- NCT06479811
- Testing
- [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II…
- Trial name
- LIGHT (NCT07325539)
- Testing
- Gemcitabine(GEM), Cisplatin, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
Patients have a type of cancer called nasopharyngeal cancer. This cancer has come back or not gone away or is at high risk for coming back after treatment (including the best treatment we know for nasopharyngeal cancer).
- Trial name
- NPC (NCT00609219)
- Testing
- autologous EBV specific CTLs
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Carcinoma
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays is concurrent chemoradiation (CCRT) based on intensity-modulated radiation therapy (IMRT).
- Trial name
- NCT02512315
- Testing
- Docetaxel (DOC), Cisplatin (DDP), Concurrent chemoradiation (CCRT)
- Where
- 4 sites in China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma
This study is to investigate the efficacy and safety of the induction chemotherapy + concurrent chemoradiotherapy（CCRT）combined with toripalimab and endostar treatment, in comparison with the induction chemotherapy + concurrent…
- Trial name
- NCT04447326
- Testing
- Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy, IC＋CCRT
- Volunteers
- 106 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients.
- Trial name
- NCT05724355
- Testing
- Dalpiciclib Isetionate Tablets, Camrelizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
- Trial name
- NCT06749899
- Testing
- QL1706, Gemcitabine, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 580 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Nasopharyngeal Neoplasms
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
This study is a phase II clinical study. Recurrence after radiotherapy patients who are failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC) were treated by cisplatin and 5-fluorouracil with Sorafenib…
- Trial name
- NCT00747799
- Testing
- Sorafenib plus Cisplatin and 5-fluorouracil
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Laryngeal Cancer, Hypopharyngeal Cancer
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) followed by radiotherapy improve progression-free survival, for patients with unresectable laryngeal/hypopharyngeal…
- Trial name
- NCT05420597
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
Nasopharyngeal Neoplasms
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive care.
- Trial name
- DIPPER (NCT03427827)
- Testing
- Camrelizumab
- Where
- 11 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC), Myelosuppression
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
This multicenter, prospective, observational cohort study aims to evaluate a previously developed dynamic risk prediction model for severe treatment-related myelosuppression in patients with nasopharyngeal carcinoma receiving…
- Trial name
- NCT07819656
- Where
- China
- Volunteers
- 1,782 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma
Anrotinib and Tirelizumab in First-line Treatment of RM-NPC
This is a prospective phase II clinical trial to evaluate the efficacy and safety of Anrotinib and Tirelizumab as a first-line treatment in patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05981157
- Testing
- Anrotinib plus Tirelizumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Nasopharyngeal Cancer
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
Nasopharyngeal cancer is a malignant tumor that arises from the cells of the nasopharyngeal epithelium, with its occurrence spread across different regions worldwide.
- Trial name
- NCT06414577
- Testing
- Irinotecan Liposomal combined With Nituzumab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- XIANG YANQUN
Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
- Trial name
- NCT07303283
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Kai Hu
Nasopharyngeal Carcinoma
Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma
The purpose of this clinical research project is to explore potential biomarkers and validate the predictive and prognostic value of molecular signature in nasopharyngeal carcinoma.
- Trial name
- NCT03025854
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to provide a more reasonable basis for clinical…
- Trial name
- NCT02293356
- Testing
- Nimotuzumab Injection
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer
Nasopharyngeal carcinoma (NPC) is endemic in our region and is the 9th most common cancer in Hong Kong. Traditionally diagnosis has been through a nasoendoscopic examination of the nasopharynx with white light followed by a…
- Trial name
- NCT04419324
- Testing
- transoral flexible endoscope with magnifying narrow band imaging
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.